Amyloid Precursor Protein (APP) and Amyloid β (Aβ) Interact with Cell Adhesion Molecules: Implications in Alzheimer's Disease and Normal Physiology

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2022 Aug 12

PMID 35959488

Authors

Grant Pfundstein

Alexander G Nikonenko

Vladimir Sytnyk

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is an incurable neurodegenerative disorder in which dysfunction and loss of synapses and neurons lead to cognitive impairment and death. Accumulation and aggregation of neurotoxic amyloid-β (Aβ) peptides generated amyloidogenic processing of amyloid precursor protein (APP) is considered to play a central role in the disease etiology. APP interacts with cell adhesion molecules, which influence the normal physiological functions of APP, its amyloidogenic and non-amyloidogenic processing, and formation of Aβ aggregates. These cell surface glycoproteins also mediate attachment of Aβ to the neuronal cell surface and induce intracellular signaling contributing to Aβ toxicity. In this review, we discuss the current knowledge surrounding the interactions of cell adhesion molecules with APP and Aβ and analyze the evidence of the critical role these proteins play in regulating the processing and physiological function of APP as well as Aβ toxicity. This is a necessary piece of the complex AD puzzle, which we should understand in order to develop safe and effective therapeutic interventions for AD.

Citing Articles

The Peripheral Amyloid-β Nexus: Connecting Alzheimer's Disease with Atherosclerosis through Shared Pathophysiological Mechanisms.

Khowdiary M, Al-Kuraishy H, Al-Gareeb A, Albuhadily A, Elhenawy A, Rashwan E Neuromolecular Med. 2025; 27(1):20.

PMID: 40032716 PMC: 11876215. DOI: 10.1007/s12017-025-08836-2.

The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment.

Kim D Curr Oncol. 2025; 32(2).

PMID: 39996888 PMC: 11854558. DOI: 10.3390/curroncol32020088.

Untangling the complex mechanisms associated with Alzheimer's disease in elderly patients using high-throughput RNA sequencing data and next-generation knowledge discovery methods: Focus on potential gene signatures and drugs for dementia.

Alkhatabi H, Pushparaj P Heliyon. 2025; 11(1):e41266.

PMID: 39834440 PMC: 11743088. DOI: 10.1016/j.heliyon.2024.e41266.

The potential link between the development of Alzheimer's disease and osteoporosis.

Nasme F, Behera J, Tyagi P, Debnath N, Falcone J, Tyagi N Biogerontology. 2025; 26(1):43.

PMID: 39832071 DOI: 10.1007/s10522-024-10181-z.

Alterations in the Processing of Platelet APP (Amyloid Beta Precursor Protein) in Alzheimer Disease: The Possible Nexus.

Al-Kuraishy H, Sulaiman G, Mohammed H, Dawood R, Albuhadily A, Al-Gareeb A Neuropsychopharmacol Rep. 2025; 45(1):e12525.

PMID: 39757022 PMC: 11702489. DOI: 10.1002/npr2.12525.

References

Heredia L, Lin R, Sola Vigo F, Kedikian G, Busciglio J, Lorenzo A . Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid beta precursor protein. Neurobiol Dis. 2004; 16(3):617-29. DOI: 10.1016/j.nbd.2004.04.015. View

Araki Y, Tomita S, Yamaguchi H, Miyagi N, Sumioka A, Kirino Y . Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein-mediated stabilization of amyloid beta-protein precursor metabolism. J Biol Chem. 2003; 278(49):49448-58. DOI: 10.1074/jbc.M306024200. View

Winther M, Berezin V, Walmod P . NCAM2/OCAM/RNCAM: cell adhesion molecule with a role in neuronal compartmentalization. Int J Biochem Cell Biol. 2011; 44(3):441-6. DOI: 10.1016/j.biocel.2011.11.020. View

Atkinson C, Zhang K, Munn A, Wiegmans A, Wei M . Prion protein scrapie and the normal cellular prion protein. Prion. 2015; 10(1):63-82. PMC: 4981215. DOI: 10.1080/19336896.2015.1110293. View

Medway C, Shi H, Bullock J, Black H, Brown K, Vafadar-Isfahani B . Using In silico LD clumping and meta-analysis of genome-wide datasets as a complementary tool to investigate and validate new candidate biomarkers in Alzheimer's disease. Int J Mol Epidemiol Genet. 2011; 1(2):134-44. PMC: 3076759. View

Petit C, Besnier L, Morel E, Rousset M, Thenet S . Roles of the cellular prion protein in the regulation of cell-cell junctions and barrier function. Tissue Barriers. 2014; 1(2):e24377. PMC: 3887058. DOI: 10.4161/tisb.24377. View

Wulf M, Senatore A, Aguzzi A . The biological function of the cellular prion protein: an update. BMC Biol. 2017; 15(1):34. PMC: 5412054. DOI: 10.1186/s12915-017-0375-5. View

Chatterjee M, Del Campo M, Morrema T, de Waal M, van der Flier W, Hoozemans J . Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):52. PMC: 5984818. DOI: 10.1186/s13195-018-0383-x. View

Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T . Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000; 20(21):7951-63. PMC: 6772747. View

10.

Strekalova H, Buhmann C, Kleene R, Eggers C, Saffell J, Hemperly J . Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging. 2005; 27(1):1-9. DOI: 10.1016/j.neurobiolaging.2004.11.013. View

11.

Chapuis J, Flaig A, Grenier-Boley B, Eysert F, Pottiez V, Deloison G . Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol. 2016; 133(6):955-966. PMC: 5427165. DOI: 10.1007/s00401-016-1652-z. View

12.

Murray H, Low V, Swanson M, Dieriks B, Turner C, Faull R . Distribution of PSA-NCAM in normal, Alzheimer's and Parkinson's disease human brain. Neuroscience. 2016; 330:359-75. DOI: 10.1016/j.neuroscience.2016.06.003. View

13.

Coburger I, Dahms S, Roeser D, Guhrs K, Hortschansky P, Than M . Analysis of the overall structure of the multi-domain amyloid precursor protein (APP). PLoS One. 2013; 8(12):e81926. PMC: 3852973. DOI: 10.1371/journal.pone.0081926. View

14.

Larson M, Sherman M, Amar F, Nuvolone M, Schneider J, Bennett D . The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci. 2012; 32(47):16857-71a. PMC: 3568961. DOI: 10.1523/JNEUROSCI.1858-12.2012. View

15.

Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta S, Singh S . Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. Eur J Med Chem. 2018; 148:436-452. DOI: 10.1016/j.ejmech.2018.02.035. View

16.

Schroeder A, de Wit J . Leucine-rich repeat-containing synaptic adhesion molecules as organizers of synaptic specificity and diversity. Exp Mol Med. 2018; 50(4):1-9. PMC: 5938020. DOI: 10.1038/s12276-017-0023-8. View

17.

Kent S, Spires-Jones T, Durrant C . The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathol. 2020; 140(4):417-447. PMC: 7498448. DOI: 10.1007/s00401-020-02196-w. View

18.

Chatterjee M, Schild D, Teunissen C . Contactins in the central nervous system: role in health and disease. Neural Regen Res. 2018; 14(2):206-216. PMC: 6301169. DOI: 10.4103/1673-5374.244776. View

19.

Asada-Utsugi M, Uemura K, Noda Y, Kuzuya A, Maesako M, Ando K . N-cadherin enhances APP dimerization at the extracellular domain and modulates Aβ production. J Neurochem. 2011; 119(2):354-63. PMC: 3395082. DOI: 10.1111/j.1471-4159.2011.07364.x. View

20.

Tian X, Liu Z, Niu B, Zhang J, Tan T, Lee S . E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011; 2011:567305. PMC: 3191826. DOI: 10.1155/2011/567305. View